Core Viewpoint - Hillenbrand, Inc. has completed the sale of its majority interest in the Milacron injection molding and extrusion business to Bain Capital for $287 million, aligning with its strategy to enhance margins by focusing on higher growth opportunities [1][4]. Group 1: Sale Details - The Milacron business was acquired by Hillenbrand in 2019 and contributed $526 million in revenues and $64 million in adjusted EBITDA in fiscal 2024 [2][3]. - Following the sale, Bain Capital owns approximately 51% of Milacron and has full operational control, while Hillenbrand retains a 49% stake [4]. Group 2: Financial Implications - Hillenbrand plans to use the net proceeds of approximately $250 million from the sale to repay its debt [4]. - The fiscal 2025 revenue outlook for Hillenbrand's remaining businesses has been updated to a range of $2.625 - $2.790 billion, down from the previous estimate of $2.925 - $3.090 billion [5]. - Total adjusted EBITDA is expected to be between $411 million and $447 million, with adjusted earnings per share anticipated in the range of $2.45 - $2.80 [6]. Group 3: Stock Performance - Hillenbrand's stock has experienced a significant decline, losing 50.5% over the past year, compared to an 11.4% decline in the industry [7].

Core Viewpoint - Hillenbrand, Inc. has completed the sale of its majority interest in the Milacron injection molding and extrusion business to Bain Capital for $287 million, retaining a 49% ownership stake [1][2][3] Group 1: Transaction Details - Bain Capital now holds approximately 51% of Milacron and has full operational control, while Hillenbrand retains a 49% stake [2] - The transaction is expected to yield after-tax net proceeds of approximately $250 million for Hillenbrand, which will be used to pay down debt [4] Group 2: Strategic Implications - This sale reflects Hillenbrand's ongoing transformation into a pure-play industrial company, allowing it to focus on core process and automation equipment for food, pharmaceutical, and polymer markets [3] - The partnership with Bain Capital is anticipated to enhance Milacron's growth potential and operational success, leveraging Bain's resources and focus [4] Group 3: Historical Context - Hillenbrand acquired Milacron Holdings Corp. in 2019, which included Milacron's injection molding and extrusion business, along with Mold-Masters, DME, and Cimcool [3] - Hillenbrand previously sold the Cimcool business in 2020 and continues to own Mold-Masters and DME [3]

Hillenbrand (HI) Q1 2025 Earnings Call February 06, 2025 08:00 AM ET Company Participants Sam Mynsberge - Director of Investor RelationsKimberly Ryan - President and Chief Executive OfficerRobert VanHimbergen - CFO & Senior VPDaniel Moore - Partner - Director of Research Conference Call Participants Mitchell Moore - Associate Analyst Operator Greetings and welcome to the Hildebrand First Quarter and Full Year twenty twenty five Earnings Call. At this time, all participants are in a listen only mode. A quest ...